Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) has shared an update.
Beijing Biostar Pharmaceuticals Co., Ltd. has announced a change in its auditing firm, with KPMG resigning due to disagreements over audit timelines and fees. The company plans to appoint Daxin Global (Hong Kong) Certified Public Accountants Ltd. as the new auditor, pending shareholder approval. This change aims to expedite the completion of the FY2024 audit, ensuring timely financial reporting and maintaining investor confidence.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of biopharmaceutical products. The company is incorporated in the People’s Republic of China and is listed on the Stock Exchange of Hong Kong.
YTD Price Performance: -77.61%
Average Trading Volume: 128,879
Technical Sentiment Signal: Strong Buy
See more insights into 2563 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects